China's Innovative Drug Exports Surge to $110B in H1 2026
Chinese innovative drug out-licensing deals hit $110 billion in H1 2026 as global pharma giants rush to license Chinese innovations.
Tag
6 articles
Chinese innovative drug out-licensing deals hit $110 billion in H1 2026 as global pharma giants rush to license Chinese innovations.
Chinese innovative drug out-licensing deals hit $110B in H1 2026 as global pharma giants partner with Chinese biotech firms for breakthrough therapies.
Belgium's Council for Permit Disputes annuls the permit for the Bioscape biotech campus in Antwerp, citing insufficient mobility analysis.
China approved 11 domestically developed new-target drugs in H1 2026, exceeding 2025's total, with world-first therapies and record out-licensing deals.
China's drug clinical trials exceeded 5,000 for the first time in 2025, hitting 5,215 registrations and doubling 2020 levels, signaling its growing role.
Xinhua calls for accelerated China innovative drug development as record BD deals top $100B and AI transforms R&D, but warns of weak basic research.